Tuesday, August 5, 2025
Science
No Result
View All Result
  • Login
  • HOME
  • SCIENCE NEWS
  • CONTACT US
  • HOME
  • SCIENCE NEWS
  • CONTACT US
No Result
View All Result
Scienmag
No Result
View All Result
Home Science News Policy

EuBiologics’ simplified OCV achieves WHO PQ

April 16, 2024
in Policy
Reading Time: 3 mins read
0
Euvichol-S
65
SHARES
592
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT

– Euvichol-S, developed jointly by EuBiologics and IVI, improves productivity by approximately 40% over Euvichol-Plus®

Euvichol-S

Credit: EuBiologics

ADVERTISEMENT

– Euvichol-S, developed jointly by EuBiologics and IVI, improves productivity by approximately 40% over Euvichol-Plus®

– Production and supply of Euvichol-S expected to help address cholera vaccine shortages

 

April 15, 2024, SEOUL, Republic of Korea – EuBiologics and the International Vaccine Institute (IVI) announced that Euvichol-S, an improved oral cholera vaccine (OCV) developed jointly by EuBiologics and IVI, has achieved World Health Organization prequalification (PQ). Euvichol-S is a new OCV that has improved productivity by about 40 percent over the existing Euvichol-Plus® by modifying the formulation and manufacturing method of the original vaccine material.

 

In May last year, EuBiologics submitted a PQ application to WHO with technical support from IVI after a field inspection of its GMP facilities by the Korean Ministry of Food and Drug Safety on behalf of WHO.  The new vaccine received an export license from KMFDS in December before winning the WHO seal of approval in about 10 months after application.

 

EuBiologics will now be able to produce and supply three oral cholera vaccines, including Euvichol® (in glass vials) and Euvichol-Plus®. There is a significant global shortage of vaccine for cholera prevention as reported recently by The New York Times, and the expected supply of Euvichol-S to UN agencies is expected to ease this supply shortage.

 

Euvichol-S was developed through technological collaboration between EuBiologics and Dr. Julia Lynch’s team at IVI, and its efficacy was demonstrated in a Phase 3 comparative clinical trial in Nepal last year. The development of the vaccine was funded by the Bill & Melinda Gates Foundation, and the vaccine will be produced and distributed by EuBiologics. After the scale-up process, Euvichol-S will be mass produced in GMP facilities at the company’s Chuncheon Plant 1 and Plant 2 in the Republic of Korea beginning in the second quarter.

 

Dr. Julia Lynch, Director of IVI’s Cholera Program, said, “The addition of Euvichol-S to global health market will contribute to easing the shortage of OCV supply amid a dire global cholera situation. IVI will continue efforts to enhance the availability of OCV worldwide and develop new and improved vaccines that are equally safe, effective, and affordable.”

 

 

###

 

 

About the International Vaccine Institute (IVI)

The International Vaccine Institute (IVI) is a non-profit international organization established in 1997 at the initiative of the United Nations Development Programme with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health.

IVI’s current portfolio includes vaccines at all stages of pre-clinical and clinical development for infectious diseases that disproportionately affect low- and middle-income countries, such as cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, COVID-19, and more. IVI developed the world’s first low-cost oral cholera vaccine, pre-qualified by the World Health Organization (WHO), and developed a new-generation typhoid conjugate vaccine that also achieved WHO prequalification in early 2024.

IVI is headquartered in Seoul, Republic of Korea with a Europe Regional Office in Sweden, an Africa Regional Office in Rwanda, a Country Office in Austria, and a Country and Project Office in Kenya. IVI additionally co-founded the Hong Kong Jockey Club Global Health Institute in Hong Kong and hosts Collaborating Centers in Ghana, Ethiopia, and Madagascar. 39 countries and the WHO are members of IVI, and the governments of the Republic of Korea, Sweden, India, Finland, and Thailand provide state funding. For more information, please visit



Share26Tweet16
Previous Post

Researchers can help shipowners achieve ambitious climate targets

Next Post

SwRI to discuss automotive decarbonization, automation at SAE International’s WCX™ 2024

Related Posts

blank
Policy

Advancing Green AI for Pakistani SMEs: Leadership, Investment, and Policy Gaps Remain

August 5, 2025
blank
Policy

Enhanced Policies and Advanced Rehabilitation: Bridging Stroke Recovery Gaps to Transform Lives

August 5, 2025
blank
Policy

Frequent Standing Linked to Improved Heart Health After Menopause, New Study Finds

August 5, 2025
blank
Policy

Healthcare Workers’ Attitudes on Influenza Vaccines in China

August 5, 2025
blank
Policy

Emergency Hospital Wait Times Continue to Climb

August 4, 2025
blank
Policy

New Rankings Reveal Journal of Medical Ethics as the World’s Leading Bioethics Publication

August 4, 2025
Next Post
HYDROGEN-POWERED HEAVY-DUTY ENGINE

SwRI to discuss automotive decarbonization, automation at SAE International’s WCX™ 2024

  • Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    27530 shares
    Share 11009 Tweet 6881
  • University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept

    941 shares
    Share 376 Tweet 235
  • Bee body mass, pathogens and local climate influence heat tolerance

    641 shares
    Share 256 Tweet 160
  • Researchers record first-ever images and data of a shark experiencing a boat strike

    506 shares
    Share 202 Tweet 127
  • Warm seawater speeding up melting of ‘Doomsday Glacier,’ scientists warn

    310 shares
    Share 124 Tweet 78
Science

Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!

RECENT NEWS

  • GABA Best Detects Early Parkinson’s Changes with RBD
  • Twentieth-Century Geography Shaping Chinese Nation Concept
  • Advanced Treatment Ensures Consistent Microplastic Removal Year-Round
  • Global Insights into Cameroonian Plasmodium falciparum Diversity

Categories

  • Agriculture
  • Anthropology
  • Archaeology
  • Athmospheric
  • Biology
  • Bussines
  • Cancer
  • Chemistry
  • Climate
  • Earth Science
  • Marine
  • Mathematics
  • Medicine
  • Pediatry
  • Policy
  • Psychology & Psychiatry
  • Science Education
  • Social Science
  • Space
  • Technology and Engineering

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 5,184 other subscribers

© 2025 Scienmag - Science Magazine

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • SCIENCE NEWS
  • CONTACT US

© 2025 Scienmag - Science Magazine

Discover more from Science

Subscribe now to keep reading and get access to the full archive.

Continue reading